David L. Cutler

TL;DR: Combination therapy with SCH 503034 and PEG-IFN-alpha-2b was well tolerated, with no clinically significant changes in safety parameters, and preliminary results of antiviral activity of the combination suggest a potential new therapeutic option for this hard-to-treat, nonresponder patient population.

TL;DR: This study establishes the dose for future testing on this schedule and provides the first evidence of successful inhibition of FT in the clinical setting and the first hint of clinical activity for this class of agents.

TL;DR: A first- order absorption, one-compartment linear model, which included first-order formation ofMTIC from TMZ and elimination of MTIC via degradation to AIC, and a peripheral distribution compartment for AIC adequately described the plasma TMZ, MTIC,and AIC concentrations, demonstrated rapid oral absorption and high systemic availability.

TL;DR: In this article, the effects of recombinant human IL-10 on LPS-induced activation of the hemostatic mechanisms in vivo were investigated in a cross-over study of human endotoxemia.

TL;DR: Plasma and urine pharmacokinetic analysis showed a greater than dose-proportional increase in drug exposure and peak plasma concentrations, with increased parameters at day 15 compared with day 1, indicating some accumulation on multiple dosing.